Name: BMY Debt Components
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#dissemination

BRISTOL-MYERS SQUIBB COMPANY (BMY) Debt Components

2026-06-30: Short-term DebtUSD (m); Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m).
2026-06-30: Short-term DebtUSD $1.03B; Long-term Debt, Current MaturitiesUSD $768.00M; Debt, CurrentUSD $1.03B; Long-term Debt, Excluding Current MaturitiesUSD $42.09B.
2026-03-31: Short-term DebtUSD $2.31B; Long-term Debt, Current MaturitiesUSD $1.99B; Debt, CurrentUSD $2.31B; Long-term Debt, Excluding Current MaturitiesUSD $42.15B.
2025-12-31: Short-term DebtUSD $2.26B; Long-term Debt, Current MaturitiesUSD $1.98B; Debt, CurrentUSD $2.26B; Long-term Debt, Excluding Current MaturitiesUSD $42.85B.

BRISTOL-MYERS SQUIBB COMPANY Debt Components

Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.

Period end	Short-term Debt USD	Long-term Debt, Current Maturities USD	Debt, Current USD	Long-term Debt, Excluding Current Maturities USD	Long-term Debt USD	Long-Term Debt, Maturity, Year One USD	Long-Term Debt, Maturity, Year Two USD	Long-Term Debt, Maturity, Year Three USD	Long-Term Debt, Maturity, Year Four USD	Long-Term Debt, Maturity, Year Five USD	Long-term Debt, Gross USD	Debt Instrument, Face Amount USD	Debt Instrument, Fair Value Disclosure USD	Debt Instrument, Basis Spread on Variable Rate pure	Debt Instrument, Unamortized Discount USD	Debt Instrument, Unamortized Premium USD	Debt Instrument Repaid Principal USD	Commercial Paper USD	Unsecured Debt, Current USD	Unsecured Debt USD	Notes Payable EUR	Notes Payable USD	Long-Term Debt, Maturity, after Year Five USD	Short-term Debt, Weighted Average Interest Rate, at Point in Time pure	Line of Credit Facility, Maximum Borrowing Capacity USD	Debt Instrument, Repurchase Amount USD	Debt Instrument, Repurchased Face Amount USD	Debt Instrument, Interest Rate, Stated Percentage pure	Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two USD	Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three USD	Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four USD	Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five USD
2026-06-30	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	6 month · $1.70B	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2026-06-30	$1.03B	$768.00M	$1.03B	$42.09B	$42.86B	(m)	(m)	(m)	(m)	(m)	(m)	$42.42B	$39.20B	(m)	$335.00M	$734.00M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2026-03-31	$2.31B	$1.99B	$2.31B	$42.15B	$44.14B	(m)	(m)	(m)	(m)	(m)	(m)	$43.66B	$40.20B	(m)	$341.00M	$743.00M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
PFIZER INC (PFE)	United States	$162.042B	31.94
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64